Impact of TP53, KEAP1 and STK11 mutations in localized-stage NSCLC: A European thoracic oncology platform lungscape project

Key Points

• Localized-stage NSCLC shows significant variations in survival rates based on tp53 mutations and other genetic factors.
• TP53 mutation status is crucial, with a correlation of 50% with poor outcomes in stage I and II NSCLC over 5 years.
• Genetic profiling was conducted using a European thoracic oncology platform, analyzing various tumor mutations.
• Understanding these mutations may enable personalized approaches in treating localized NSCLC, needing further validation.